Norplant® consensus statement and background review

Contraception

Volumn 57, Issue 1, 1998, Pages 1-9

  Fraser, Ian S ^a   Tiitinen, Aila ^a   Affandi, Biran ^a   Brache, Vivian ^a   Croxatto, Horacio B ^a   Diaz, Soledad ^a   Ginsburg, Jean ^a   Gu, Sujuan ^a   Holma, Pentti ^a   Johansson, Elof ^a   Meirik, Olav ^a   Mishell Jr , Daniel R ^a   Nash, Harold A ^a   Von Schoultz, Bo ^a   Sivin, Irving ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

LEVONORGESTREL; CONTRACEPTIVE AGENT; PROGESTERONE DERIVATIVE;

ADULT; CONTRACEPTION; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG IMPLANT; ECHOGRAPHY; EMBRYO DEVELOPMENT; FAMILY PLANNING; FEMALE; FEMALE FERTILITY; HUMAN; INFORMATION PROCESSING; MAJOR CLINICAL STUDY; OVULATION INHIBITION; REVIEW; TRANSDERMAL DRUG ADMINISTRATION; UNITED KINGDOM; UNITED STATES; CLINIC ACTIVITIES; COMPARATIVE STUDY; CONFERENCE PAPER; CONSENSUS DEVELOPMENT; CONTRACEPTION CONTINUATION--DETERMINANTS; CONTRACEPTION TERMINATION; CONTRACEPTIVE AGENTS, FEMALE--PHARMACODYNAMICS; CONTRACEPTIVE AGENTS, FEMALE--SIDE EFFECTS; CONTRACEPTIVE AGENTS, PROGESTIN--PHARMACODYNAMICS; CONTRACEPTIVE AGENTS, PROGESTIN--SIDE EFFECTS; CONTRACEPTIVE AGENTS--PHARMACODYNAMICS; CONTRACEPTIVE AGENTS--SIDE EFFECTS; CONTRACEPTIVE IMPLANTS; CONTRACEPTIVE METHODS; CONTRACEPTIVE USAGE; COUNSELING; DEVELOPING COUNTRY; EDUCATION; FAMILY PLANNING PROGRAMS; INFORMED CONSENT; LEVONORGESTREL--PHARMACODYNAMICS; LEVONORGESTREL--SIDE EFFECTS; LITERATURE REVIEW; ORGANIZATION AND MANAGEMENT; PROGRAM ACTIVITIES; PROGRAMS; TRAINING ACTIVITIES; TRAINING PROGRAMS; WORLD;

CLINIC ACTIVITIES; CONTRACEPTION; CONTRACEPTION CONTINUATION--DETERMINANTS; CONTRACEPTION TERMINATION; CONTRACEPTIVE AGENTS, FEMALE--PHARMACODYNAMICS; CONTRACEPTIVE AGENTS, FEMALE--SIDE EFFECTS; CONTRACEPTIVE AGENTS, PROGESTIN--PHARMACODYNAMICS; CONTRACEPTIVE AGENTS, PROGESTIN--SIDE EFFECTS; CONTRACEPTIVE AGENTS--PHARMACODYNAMICS; CONTRACEPTIVE AGENTS--SIDE EFFECTS; CONTRACEPTIVE IMPLANTS; CONTRACEPTIVE METHODS; CONTRACEPTIVE USAGE; COUNSELING; DEVELOPING COUNTRIES; EDUCATION; FAMILY PLANNING; FAMILY PLANNING PROGRAMS; INFORMED CONSENT; LEVONORGESTREL--PHARMACODYNAMICS; LEVONORGESTREL--SIDE EFFECTS; LITERATURE REVIEW; ORGANIZATION AND ADMINISTRATION; PROGRAM ACTIVITIES; PROGRAMS; TRAINING ACTIVITIES; TRAINING PROGRAMS; WORLD;

CONTRACEPTIVE AGENTS, FEMALE; DRUG IMPLANTS; FEMALE; HUMANS; LEVONORGESTREL; PROGESTERONE CONGENERS;

EID: 0031596604     PISSN: 00107824     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0010-7824(97)00200-X     Document Type: Article

References (31)

1. 1. Choice and challenge: global teamwork in developing a contraceptive implant. Population Council, 1990.
2. 2. Facts about an implantable contraceptive. WHO Bull 1985;63:485-94.
3. 3. Norplant® levonorgestrel Implants. A summary of scientific data. Population Council, 1990.
4. 4. McIntosh N, Blouse A, Schaefer L. Norplant® implant guidelines for family planning service programs. A Problem Solving Reference Manual. 1995 JHPIEGO Corporation Norplant® Implants Trainer's Notebook. JHPIEGO Corporation, 1995.
5. 5. Moore DE, Roy S, Stanczyk FZ, Mishell DR Jr. Bleeding and serum d-norgestrel, estradiol, and progesterone patterns in women using d-norgestrel subdermal polysiloxane capsules for contraception. Contraception 1978;17: 315-40.
6. 6. Sivin I, Mishell DR Jr, Darney P, et al. Efficacy, side effects and acceptability of soft tubing Norplant® capsule implants in the United States: a 5-year study. Obstet Gynecol (in press).
7. 7. Alvarez F, Brache V, Tejada AS, et al. Abnormal endocrine profile among women with confirmed or presumed ovulation during long-term Norplant® use. Contraception 1986;33:111-9.
8. 8. Brache V, Alvarez-Sanches F, Faundes A, et al. Ovarian endocrine function through five years of continuous treatment with Norplant® subdermal contraceptive implants. Contraception 1990;41:169-77.
9. 9. Croxatto HB, Diaz S, Pavez M, et al. Plasma progesterone levels during long-term treatment with levonorgestrel silastic implants. Acta Endocrinol 1982;101:307-11.
10. 10. Brache V, Faundes A, Johansson E, et al. Anovulation, inadequate luteal phase and poor sperm penetration in cervical mucus during prolonged use of Norplant® implants. Contraception 1985;31:261-73.
11. 11. Shoupe D, Horenstein H, Mishell DR Jr, et al. Characteristics of ovarian follicular development in NORPLANT® users. Fertil Steril 1991;55:766-70.
12. 12. Croxatto HB, Diaz S, Salvatierra AM, et al. Treatment with Norplant® subdermal implants inhibits sperm penetration through cervical mucus in vitro. Contraception 1987;36:193-201.
13. 13. Darney PD, Klaisle CM, Tanner S, et al. Sustained-release contraceptives. Curr Probl Obstet Gynecol Fertil 1990;13:87-96.
14. 14. Croxatto HB, Diaz S, Pavez M, et al. Estradiol plasma levels during long-term treatment with Norplant® subdermal implants. Contraception 1988;38:465-75.
15. 15. Shoupe D, Mishell DR Jr, Bopp BL, Fielding M. The significance of bleeding patterns in Norplant® implant users. Obstet Gynecol 1991;77:256-60.
16. 16. Nilsson CG, Holma P. Menstrual blood loss with contraceptive subdermal levonorgestrel implants. Fertil Steril 1981;35:304-6.
17. 17. Sivin I. International experience with Norplant® and Norplant®-2. Stud Fam Plann 1988;19:81-94.
18. 18. Sivin I. Data from Population Council, New York City, New York.
19. 19. Croxatto HB, Diaz S, Robertson DN, et al. Clinical chemistry in women treated with levonorgestrel implants (Norplant®) or a TCu 200 IUD. Contraception 1983;27:281-288.
20. 20. Shaaban MM, Elwan SI, El-Sharkawy MM, et al. Effects of subdermal levonorgestrel contraceptive implants, Norplant®, on liver functions. Contraception 1984;30: 407-12.
21. 21. Singh K, Viegas OAC, Loke DFM, et al. Effect of Norplant® implants on liver, lipid and carbohydrate metabolism. Contraception 1992;45:141-53.
22. 22. Shaaban MM, Elwan S, Kabsh M, et al. Effect of levonorgestrel contraceptive implants, Norplant® on blood coagulation. Contraception 1984;30:421-30.
23. 23. Singh K, Viegas OAC, Koh SCL, Ratnam SS. Effect of long-term use of Norplant® implants on haemostatic function. Contraception 1992;45:203-19.
24. 24. Darney PD, Atkinson E, Tanner S, et al. Acceptance and perceptions of Norplant® among users in San Francisco, USA. Stud Fam Plann 1990;21:152-60.
25. 25. Sivin I. Contraception with Norplant® implants. Hum Reprod 1994;9:1818-26.
26. 26. Cromer BA, Blair JM, Mahan JD, et al. A prospective comparison of bone density in adolescent girls receiving depot medroxyprogesterone acetate (Depo-Provera), levonorgestrel (Norplant), or oral contraceptives. J Pediatr 1996;129:671-6.
27. 27. Naessen T, Olsson S-E, Gudmundsson J. Differential effects on bone density of progestogen-only methods for contraception in premenopausal women. Contraception 1995;52:35-39.
28. 28. World Health Organization. Improving Access to Quality Care in Family Planning. Medical Eligibility Criteria for Contraceptive Use. WHO/FPP/96.9. WHO, Geneva, 1996.
29. 29. Gu S-J, Sivin I, Du M-K, et al. Effectiveness of Norplant® implants through 7 years: a large scale study in China. Contraception 1995;52:99-103.
30. 30. UNDP/UNFPA/WHO/World Bank Special Programme of Research, Development and Research Training in Human Reproduction. Unpublished data, 1997.
31. 31. Sivin I, Viegas OAC, Campondonico I, et al. Clinical performance of a new two-rod levonorgestrel contraceptive implant: a three-year randomized study with Norplant® implants as controls. Contraception 1997;55:73-80.